AXSM - Axsome Therapeutics, Inc.
IEX Last Trade
87.01
-4.470 -5.137%
Share volume: 0
Last Updated: Tue 24 Dec 2024 05:59:59 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
19.80%
PREVIOUS CLOSE
CHG
CHG%
$91.48
-4.47
-4.89%
Fundamental analysis
29%
Profitability
25%
Dept financing
19%
Liquidity
75%
Performance
25%
Performance
5 Days
-4.10%
1 Month
-10.76%
3 Months
-3.24%
6 Months
10.13%
1 Year
13.27%
2 Year
17.92%
Key data
Stock price
$87.01
DAY RANGE
$86.08 - $91.48
52 WEEK RANGE
$68.14 - $105.00
52 WEEK CHANGE
$4.07
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/04/2024
Company detail
CEO: Herriott Tabuteau
Region: US
Website: axsome.com
Employees: 380
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: axsome.com
Employees: 380
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Axsome Therapeutics, Inc. engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the. treatment of smoking cessation. The firm was incorporated in 2012 and is based in New York, New York.
Recent news